0001012975-17-000446.txt : 20170523 0001012975-17-000446.hdr.sgml : 20170523 20170523151955 ACCESSION NUMBER: 0001012975-17-000446 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170523 DATE AS OF CHANGE: 20170523 EFFECTIVENESS DATE: 20170523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Centrexion Therapeutics Corp CENTRAL INDEX KEY: 0001592052 IRS NUMBER: 320402377 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-287301 FILM NUMBER: 17863595 BUSINESS ADDRESS: STREET 1: 509 S. EXETER ST., SUITE 202 CITY: BALTIMORE STATE: MD ZIP: 21202 BUSINESS PHONE: 212-956-1111 MAIL ADDRESS: STREET 1: 509 S. EXETER ST., SUITE 202 CITY: BALTIMORE STATE: MD ZIP: 21202 FORMER COMPANY: FORMER CONFORMED NAME: Centrexion Corp DATE OF NAME CHANGE: 20131114 D 1 primary_doc.xml X0707 D LIVE 0001592052 Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 617-837-6911 DELAWARE Centrexion Corp Corporation true 2013 Arnold Oronsky c/o Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 Director James N. Campbell c/o Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 Executive Officer Director Jeffrey B. Kindler c/o Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 Executive Officer Director Randall M. Stevens c/o Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 Executive Officer Sol J. Barer c/o Centrexion Therapeutics Corp 200 State Street Boston MA MASSACHUSETTS 02109 Director Biotechnology Decline to Disclose 06b false 2017-04-28 false true true Convertible Notes false 0 Brookline Capital Markets None CIM Securities, LLC 120852 509 Madison Avenue, Suite 1006 New York NY NEW YORK 10022 All States false Indefinite 5285000 Indefinite false 40 212450 0 0 false Centrexion Therapeutics Corp /s/ Gregg Beloff Gregg Beloff Chief Financial Officer 2017-05-23